This month marks the start of a new era for GlaxoSmithKline, with Emma Walmsley taking over from Sir Andrew Witty – and big pharma's first female CEO has said she is prepared to make tough ...

(Bloomberg) -- When Elliott Investment Management came calling for the ouster of Emma Walmsley ... In an early gaffe that ...

At the Financial Times (FT) Global Pharma and Biotech Summit in London on 6 November, GSK CEO Emma Walmsley ... and I hope that science and truth will prevail,” concluded Walmsley.

GlaxoSmithKline’s CEO Emma Walmsley has said the company hopes to get at least six new drug approvals in the next year. In an interview at the JP Morgan Healthcare Conference in San Francisco ...

GSK CEO Emma Walmsley’s $13 million salary is predicated on picking the right people to steer cutting-edge drug development for the world’s most challenging diseases. During her eight years at ...

CEO Emma Walmsley says. Speaking at the CEO Times Summit in London, Walmsley highlights the U.K. pharmaceutical company's refocused R&D strategy, with investments concentrated in the U.K., U.S ...

The British drugs group, led by boss Emma Walmsley, is using the data of 1.4m adults aged 65 and 66 to examine the impact of its Shingrix shot. GSK shares inched up 0.1 per cent, or 1p ...